{"ticker": {"uuid": "e3a3bb2d-c3ad-4d6f-a432-2b31ecd1b56f", "symbol": "NNNN", "name": "Anbio Biotechnology Class A Ordinary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Instruments & Supplies"}, "articles": [{"title": "Anbio Biotechnology Files Mixed Shelf Registration", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/anbio-biotechnology-files-mixed-shelf-215225562.html", "source_name": "MT Newswires", "published_at": "2026-07-09T21:52:25+00:00", "published_display": "09 Jul 2026 21:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Anbio Biotechnology \u2013 NASDAQ:NNNN", "summary": "This article provides financial information for Anbio Biotechnology (NASDAQ:NNNN), specifically focusing on its forward price-to-earnings ratio. The content, sourced from TradingView, indicates \"No trades\" and is primarily a placeholder or incomplete financial data page, emphasiz", "url": "https://www.tradingview.com/symbols/NASDAQ-NNNN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T18:40:11", "published_display": "03 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Anbio Biotechnology Class A \u2013 FWB:N3B", "summary": "This article provides a brief financial overview for Anbio Biotechnology Class A (FWB:N3B), focusing on its price-to-earnings forward metric. The content indicates that market data is provided by ICE Data Services and reference data by FactSet, with all copyrights reserved up to ", "url": "https://www.tradingview.com/symbols/FWB-N3B/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:10:17", "published_display": "30 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Soars After Surprise Media Spotlight", "summary": "Anbio Biotechnology Class A (NNNN) shares are surging after being featured in a Benzinga article on top healthcare stocks for Q2. This rally is attributed to fresh media exposure, renewed optimism for Anbio's diagnostic portfolio, and a technical rebound, rather than broader sect", "url": "https://www.tipranks.com/news/catalyst/anbio-biotechnology-soars-after-surprise-media-spotlight", "source_name": "TipRanks", "published_at": "2026-06-22T14:40:14", "published_display": "22 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top 3 Health Care Stocks You'll Regret Missing In Q2 - iRhythm Holdings (NASDAQ:IRTC), Anbio Biotechnolog", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPb2ZIV3pJcVZ3RUNiXy04TTNESGhKcjdEMG91VGt5eDFkTjdyd2x3OVE1Q1dqSUdxWG1jbDEwbUFUVnpzZTBrZjFfSjZtMDlCWFJNUjJud0Q2LUw2ankyREpuRDZJOThKcFFjTlRFV3BtZWJYMGJoelY0amp3d2R1eVE5V2l2LW1HQlB3MmNYMzBNQmEtQThVWUdaQWZ3aHRHSjFIZmJoTGZ3OW95MUw0eHRnZFNBQm8?oc=5", "source_name": "Benzinga", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Holds Steady Near $34.41 as Trading Volume Remains Moderate - VOLD Alert", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQTWNPLXVBNS1ucGlGVHlLMnlENEFCOWNLR1V0bFBOZmNJd2NGbkhHei1qREpqLTZMbnpKVl9jV1dHbXAyYk10TUZaZUtnbzR6QlByQmVkQ1JLVjY0T1FPOVZ1VGdfSk9tVXRpWlpoUy01NDNibkZKN2doeXVxU3dCWjZZQ2FVZlVXaEYxZXhEdHoxdXpxUm9HTkRnWmFnN2h6bTVyUURBelFwU2FZXzJDa0dnNVRnTVVnSjl5SEJ3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology (NNNN) Surges 5%: Key Levels and What to Watch - Put Dominated", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPM2NGSUpWUkhJWXEzeWxneElLdHdXc0JveURSZk5zNkRTa3o3bXJXSE12VmdZZ1ZYUlp2WWNwMV9ia0x0TUhqaXNxYXFtcW5BVTh1UjVXeDFtWjhyVXQ1WUdNVjYyTEJFMlFJNGNzdjhyRVRCNVY2ZEl3SWliUmZCbWUzVGk2cnBXVnl4TVRrcWxSS2hzYTF4TWloTE9QSEpJMVBvUmdvR2kxOFl1TkhlWkln?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Anbio Biotechnology (NNNN) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Control shifts as Anbio (NNNN) boosts Class B voting power", "summary": "Anbio Biotechnology shareholders have approved significant changes to the company's capital structure and governance, including a Share Capital Reduction, an Authorised Share Capital Increase, and a substantial boost in voting rights for Class B shares from 50 to 500 votes per sh", "url": "https://www.stocktitan.net/sec-filings/NNNN/6-k-anbio-biotechnology-current-report-foreign-issuer-48a739cd67a1.html", "source_name": "Stock Titan", "published_at": "2026-05-19T10:09:26", "published_display": "19 May 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Free cash flow per share of Anbio Biotechnology Class A \u2013 FWB:N3B", "summary": "The article presents information related to the free cash flow per share for Anbio Biotechnology Class A, traded on the Frankfurt Stock Exchange under the symbol N3B. It appears to be a financial data snippet from TradingView, indicating the period, value, and change in free cash", "url": "https://www.tradingview.com/symbols/FWB-N3B/financials-statistics-and-ratios/free-cash-flow-per-share/", "source_name": "TradingView", "published_at": "2026-05-01T13:39:17", "published_display": "01 May 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Calls May 15 Shareholder Votes on Sweeping Capital and Governance Overhaul", "summary": "Anbio Biotechnology (NNNN) is holding shareholder meetings on May 15, 2026, to approve significant changes to its capital and governance structure. These proposed changes include a reduction in par value, a substantial increase in authorized share capital to introduce new Class C", "url": "https://www.tipranks.com/news/company-announcements/anbio-biotechnology-calls-may-15-shareholder-votes-on-sweeping-capital-and-governance-overhaul", "source_name": "TipRanks", "published_at": "2026-04-27T23:09:35", "published_display": "27 Apr 2026 23:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology (NNNN) files 20-F/A to mark well-known seasoned issuer", "summary": "Anbio Biotechnology (NNNN) has filed an Amendment No. 1 to its Form 20-F annual report for the year ended December 31, 2025. The sole purpose of this amendment is to update the cover page to indicate that the company is a well-known seasoned issuer, as defined in Rule 405 of the ", "url": "https://www.stocktitan.net/sec-filings/NNNN/20-f-a-anbio-biotechnology-amends-annual-report-foreign-issuer-56acd8776418.html", "source_name": "Stock Titan", "published_at": "2026-04-09T09:39:42", "published_display": "09 Apr 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Head-To-Head Analysis: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN)", "summary": "This article provides a head-to-head analysis of Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX), comparing them across valuation, earnings, insider and institutional ownership, profitability, and analyst recommendations. Anbio Biotechnology shows higher revenue and ", "url": "https://www.defenseworld.net/2026/03/07/head-to-head-analysis-oncocyte-nasdaqimdx-anbio-biotechnology-nasdaqnnnn-2.html", "source_name": "Defense World", "published_at": "2026-03-09T07:09:43", "published_display": "09 Mar 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Review", "summary": "This article provides a head-to-head comparison between Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX), two manufacturing companies, evaluating them on profitability, earnings, valuation, analyst recommendations, and institutional/insider ownership. Anbio Biotechnol", "url": "https://www.defenseworld.net/2026/03/09/oncocyte-nasdaqimdx-versus-anbio-biotechnology-nasdaqnnnn-head-to-head-review.html", "source_name": "Defense World", "published_at": "2026-03-09T05:51:22", "published_display": "09 Mar 2026 05:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Financial Analysis: Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN)", "summary": "This article compares Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX) based on financial metrics, institutional ownership, analyst recommendations, and profitability. Anbio Biotechnology, a company focused on in vitro diagnostics, demonstrates higher revenue and earn", "url": "https://www.defenseworld.net/2026/03/06/financial-analysis-oncocyte-nasdaqimdx-and-anbio-biotechnology-nasdaqnnnn-2.html", "source_name": "Defense World", "published_at": "2026-03-07T04:53:04", "published_display": "07 Mar 2026 04:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology: Improved Margins, Still Priced For Growth That Isn't Showing Up", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNb2V5ZkdCSDl3MWVheWhudnNHUG1lM20tWUJQQk95SlVGV0FwRmlSX25xYzktZHVfbEU2YWxKMDNDck56RjJXVnRzVFJaWFJOcG5hN2VQZjd5WEFYUU9JUkJiQkN4aHJuX1dhRWdvd2p0aHZQNWhCcnhhUXl0dVVQQWNhYWxLd3ZLNmtuVGJjSTRxd3Z6XzlnSGgycHZVUW1pTFVkb05EbmhHWHFVSk1LZDIwRmJxVmJIODc2Z3NKaDc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head to Head Contrast", "summary": "This article compares Oncocyte (IMDX) and Anbio Biotechnology (NNNN) based on various financial metrics and analyst recommendations. Anbio Biotechnology demonstrates higher revenue and profitability, leading it to outperform Oncocyte in 6 out of 10 comparison factors. The article", "url": "https://www.defenseworld.net/2026/03/01/oncocyte-nasdaqimdx-versus-anbio-biotechnology-nasdaqnnnn-head-to-head-contrast.html", "source_name": "Defense World", "published_at": "2026-03-01T07:52:24", "published_display": "01 Mar 2026 07:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Forecast & Price Prediction 2026\u20132030", "summary": "This article provides a comprehensive stock forecast and price prediction for Anbio Biotechnology Class A Ordinary Shares (NNNN) from 2026 to 2030, and further projections up to 2057. It presents yearly and monthly estimated price ranges, details technical analysis, and includes ", "url": "https://coincodex.com/stock/NNNN/price-prediction/", "source_name": "CoinCodex", "published_at": "2026-03-01T01:51:35", "published_display": "01 Mar 2026 01:51", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Critical Comparison: Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN)", "summary": "This article compares Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX) across various financial metrics, analyst recommendations, and profitability. Anbio Biotechnology outperforms Oncocyte in six out of ten comparison factors, including revenue and earnings. However,", "url": "https://www.defenseworld.net/2026/02/26/critical-comparison-oncocyte-nasdaqimdx-vs-anbio-biotechnology-nasdaqnnnn.html", "source_name": "Defense World", "published_at": "2026-02-27T01:51:35", "published_display": "27 Feb 2026 01:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Comparing Anbio Biotechnology (NASDAQ:NNNN) & Oncocyte (NASDAQ:IMDX)", "summary": "This article compares Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX), two manufacturing companies, across various financial metrics, analyst recommendations, and ownership details. While analysts favor Oncocyte due to a higher potential upside, Anbio Biotechnology s", "url": "https://www.defenseworld.net/2026/02/25/comparing-anbio-biotechnology-nasdaqnnnn-oncocyte-nasdaqimdx-2.html", "source_name": "Defense World", "published_at": "2026-02-25T06:53:24", "published_display": "25 Feb 2026 06:53", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Replaces Auditor to Safeguard 2025 Reporting Timeline", "summary": "Anbio Biotechnology dismissed its auditor, HTL International, LLC, and appointed GGF CPA LTD on February 11, 2026. This change was made to ensure the timely completion of its 2025 Form 20-F financial reporting, with no disagreements cited between Anbio and the former auditor. The", "url": "https://www.tipranks.com/news/company-announcements/anbio-biotechnology-replaces-auditor-to-safeguard-2025-reporting-timeline", "source_name": "TipRanks", "published_at": "2026-02-17T22:57:57", "published_display": "17 Feb 2026 22:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Stock Price Today | NASDAQ: NNNN Live", "summary": "This article provides live stock exchange data for Anbio Biotechnology (NASDAQ: NNNN), including its current stock price, symbol, trading exchange, and various financial metrics. It also features a \"Scorecard\" detailing the company's health, fair value, technical analysis, and re", "url": "https://www.investing.com/equities/anbio-biotechnology", "source_name": "Investing.com", "published_at": "2026-02-04T17:59:09", "published_display": "04 Feb 2026 17:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Class A Shares Surge After Volatility Pause", "summary": "Anbio Biotechnology Class A shares surged following a volatility pause, indicating significant market interest. This rise coincided with the appointment of Michael Zhang as chair of the audit committee, a move designed to enhance governance, investor confidence, and financial tra", "url": "https://www.tipranks.com/news/catalyst/anbio-biotechnology-class-a-shares-surge-after-volatility-pause", "source_name": "TipRanks", "published_at": "2026-02-02T19:28:53", "published_display": "02 Feb 2026 19:28", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology (NNNN) 10K Form and Latest SEC Filings 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE1mNUFlVG1MZnloVDN6WnlZM0ZhQk9Bcy1yLVdFdmMxdk9ZSS1YR1Q1QmR5ZGE0cDVoWGU2UWxWOXl4Qklsd2J4UDY1X2I0M2ZfM3JEeHA2cGZnMDY3QWtiR05sR0pqdzhlWXc?oc=5", "source_name": "MarketBeat", "published_at": "2026-01-28T13:52:53+00:00", "published_display": "28 Jan 2026 13:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026", "summary": "Anbio Biotechnology announced board and committee changes effective January 21, 2026. Michael Zhang has been appointed as a director, the Chair of the Audit Committee, and a member of both the Nominating and Compensation Committees, replacing Kenneth Li. Kenneth Li's departure wa", "url": "https://www.marketscreener.com/news/anbio-biotechnology-announces-board-and-committee-changes-effective-january-21-2026-ce7e5bd8db89f124", "source_name": "www.marketscreener.com", "published_at": "2026-01-26T18:29:41", "published_display": "26 Jan 2026 18:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Strengthens Board Oversight With Appointment of Michael Zhang as Audit Committee Chair", "summary": "Anbio Biotechnology has appointed Michael Zhang as director, audit committee chair, and committee member, effective January 21, 2026. Zhang is recognized as an independent audit committee financial expert under U.S. and Nasdaq rules, and his appointment is expected to enhance the", "url": "https://www.tipranks.com/news/company-announcements/anbio-biotechnology-strengthens-board-oversight-with-appointment-of-michael-zhang-as-audit-committee-chair", "source_name": "TipRanks", "published_at": "2026-01-26T11:58:25", "published_display": "26 Jan 2026 11:58", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology (NASDAQ:NNNN) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-01T08:00:00+00:00", "published_display": "01 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Posts Higher Margins and Profits Despite Revenue Dip in First Half of 2025", "summary": "Anbio Biotechnology (NNNN) reported financial results for the first half of 2025, showing a revenue decrease to $4.6 million from $5.8 million, but a significant rise in gross profit to $4.2 million, with margins expanding to 92.3%. Net income also increased to $3.8 million, demo", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NNNN-Q/pressreleases/36846367/anbio-biotechnology-posts-higher-margins-and-profits-despite-revenue-dip-in-first-half-of-2025/", "source_name": "The Globe and Mail", "published_at": "2026-01-01T03:09:49", "published_display": "01 Jan 2026 03:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Year-End Review | The 2025 US IPO Gainers List is Out! Anbio Biotechnology Soars Over 570%, 'First Stablecoin Stock' Circle Surges More Than 180%", "summary": "The 2025 U.S. IPO market saw a significant recovery, driven by a stabilizing macroeconomic environment and renewed investor confidence, with 202 IPOs raising $44 billion. Technology and healthcare companies dominated the top performers, highlighting 'polarization' and 'sector foc", "url": "https://news.futunn.com/en/post/66532350/year-end-review-the-2025-us-ipo-gainers-list-is", "source_name": "\u5bcc\u9014\u8d44\u8baf", "published_at": "2025-12-27T06:58:33", "published_display": "27 Dec 2025 06:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NNNN SEC Filings - ANBIO BIOTECHNOLOGY 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for ANBIO BIOTECHNOLOGY (NNNN) SEC filings, including 10-K, 10-Q, 8-K reports, and insider trading forms. It details recent filings such as initial Form 3 reports from directors and executives, and significant corporate actions like cha", "url": "https://www.stocktitan.net/sec-filings/NNNN/", "source_name": "Stock Titan", "published_at": "2025-11-14T00:39:22", "published_display": "14 Nov 2025 00:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Anbio Biotechnology\u2019s Stock is Tumbling - TipRanks", "summary": "Anbio Biotechnology Class A (NNNN) is experiencing significant stock volatility, including recent trading halts due to large price swings. The stock initially surged but has faced multiple declines, reflecting investor uncertainty and broader market conditions affecting its perce", "url": "https://www.tipranks.com/news/catalyst/why-anbio-biotechnologys-stock-is-tumbling", "source_name": "TipRanks", "published_at": "2025-10-13T16:24:27", "published_display": "13 Oct 2025 16:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NNNN News Today | Why did Anbio Biotechnology stock go up today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYEFVX3lxTE5EM0g0bU9zZHpHVlVsWG5ZZGR4NGdrMXNuVEVRUkdWT0V3bUR6VERHVXVxckpWNEg4c3ItakRNcWdBRFBGbW9lVmZpMDREbkhESXh3NlFhMl9QUVZBTjBGSA?oc=5", "source_name": "MarketBeat", "published_at": "2025-09-18T17:08:47+00:00", "published_display": "18 Sep 2025 17:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here Is What You Need To Know Before Investing In Anbio Biotechnology (NNNN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOUjZDV2wtYTdmNVh3ZGNlRmhNNUVIdlFCb3VsMXNXaWJBbDJ5MUswOHJydlI1UUY0TjRBOGp6NnBfQ2NWZzN5dDYwbERfd3VwSldUYm5NQmlBTGVPQkN2Vk9hNWxuRm1qdW0tdTNBQTNlTlZvM09xd2lMV0FqREFEVDlkSElzZ3Q1dGJZdGpR?oc=5", "source_name": "Market source", "published_at": "2025-07-11T07:00:00+00:00", "published_display": "11 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANBIO BIOTECHNOLOGY (NNNN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9YMmdjUmlWVjc0Uzl6bG16RWlEYlB2MzBHNWRSRU5fZkpWWV9wdXZfaXdLa2NmSWM1dHU1aE1XRm9ROXc3LTItbGlWVUt0SlFiOFhn?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-28T14:05:31+00:00", "published_display": "28 Apr 2025 14:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NNNN Stock Price, News & Analysis", "summary": "Anbio Biotechnology (Nasdaq: NNNN) is a global in vitro diagnostics (IVD) company specializing in diagnostic products for human and veterinary health, utilizing five key platforms for biomarker detection. The company has a global presence across the EU, APAC, and the Americas, wi", "url": "https://www.stocktitan.net/overview/NNNN/", "source_name": "Stock Titan", "published_at": "2025-04-28T09:39:09", "published_display": "28 Apr 2025 09:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Free float of Anbio Biotechnology \u2013 NASDAQ:NNNN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOekFTYnBNdVhKT01rODZmR2ZRT3ZIVGwwbXEzaThFdzdfcFpiSUI2engxRTdOTTN0NFlsR1pYSy1HOGdwOEoyLTFlWXBpWlJaM1NVTU9HZmR3NHZjRmdhNXdXaWt3NXNidlUzNHpoUnVBeUpOdFFaMjEzY2tTVlZraGVTUE55dTQtNTJXc0xaMmRFdl82NUNtUmZKN1FuSFNZV1lRbHdQVk9odw?oc=5", "source_name": "TradingView", "published_at": "2025-03-16T05:17:58+00:00", "published_display": "16 Mar 2025 05:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology (NNNN) Company Information", "summary": "This report provides comprehensive company information for Anbio Biotechnology (NNNN), detailing its market capitalization, employee growth, and exchange listings. It includes key data like the company's founding year, industry, sector, shares outstanding, and website. The report", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nnnn/anbio-biotechnology/information", "source_name": "Simply Wall Street", "published_at": "2025-02-21T10:08:51", "published_display": "21 Feb 2025 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology (NNNN) Leadership & Management Team Analysis", "summary": "This article provides an analysis of Anbio Biotechnology's leadership and management team. It details information about CEO Michael Lau's compensation and tenure, along with an overview of the leadership team and board members. The report also includes recent management updates a", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nnnn/anbio-biotechnology/management", "source_name": "Simply Wall St", "published_at": "2025-02-21T04:52:03", "published_display": "21 Feb 2025 04:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Anbio Biotechnology (NNNN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9Wc1Zuci1YdW56SjFJMUFyaWpOQmZ1N0Y1ZlpRTlpYdU5sUjlIaEpSS18teFlXOW9rUDAyR1lpVUF5LUFSYXlmNTdkaVA3LURxUzhTUGJqbkZUSFNIc3dpWFBKMmF4TWNjN3lScQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-02-21T02:43:38+00:00", "published_display": "21 Feb 2025 02:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Announces Closing of Initial Public Offering", "summary": "Anbio Biotechnology has announced the closing of its initial public offering, raising gross proceeds of US$8 million from the sale of 1,600,000 Class A ordinary shares at US$5.00 each. The shares began trading on the Nasdaq Global Market under the ticker symbol \"NNNN\" on February", "url": "https://www.globenewswire.com/news-release/2025/02/20/3029797/0/en/anbio-biotechnology-announces-closing-of-initial-public-offering.html", "source_name": "GlobeNewswire", "published_at": "2025-02-20T12:40:43", "published_display": "20 Feb 2025 12:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NNNN - ANBIO BIOTECHNOLOGY Latest Stock News & Market Updates", "summary": "This page provides the latest news and market updates for Anbio Biotechnology (NNNN), a global in vitro diagnostics company. It highlights recent product launches, such as the Chikungunya Rapid Test and the AP-100 Ultra-Fast PCR system, as well as the company's participation in i", "url": "https://www.stocktitan.net/news/NNNN/", "source_name": "Stock Titan", "published_at": "2025-02-20T09:57:45", "published_display": "20 Feb 2025 09:57", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Closes Initial Public Offering, Raising $8 Million on Nasdaq", "summary": "Anbio Biotechnology has successfully completed its initial public offering, raising $8 million by offering 1,600,000 Class A ordinary shares at $5.00 each. The shares commenced trading on Nasdaq under the ticker \"NNNN\" on February 19, 2025. The capital will be utilized for expand", "url": "https://www.nasdaq.com/articles/anbio-biotechnology-closes-initial-public-offering-raising-8-million-nasdaq", "source_name": "Nasdaq", "published_at": "2025-02-20T08:09:19", "published_display": "20 Feb 2025 08:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANBIO BIOTECHNOLOGY (NNNN) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE9QMDg1US1yaTlPcVJCYXZEanNRMUpWemRyRWplNGRlcFJDWUR5SVY5YmhISVlTQWp1WjZQcXFMZk9yeU9RUFVFNXlwbVVvQQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-02-20T08:00:00+00:00", "published_display": "20 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NNNN Stock Price and Chart \u2014 NASDAQ:NNNN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1wU25tMms5WVliZG5Bc1Z3SUtzb19ydkVnTG43ZzdEdGpfRWkwcWpQZDJMV29NeUJ5cFA1di1nUWo3TjJXM2hXUHh0TkZjTEpkRlVZZEJYNFZuQjVs?oc=5", "source_name": "TradingView", "published_at": "2025-02-19T18:21:46+00:00", "published_display": "19 Feb 2025 18:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Anbio Biotechnology Files Mixed Shelf Registration", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/anbio-biotechnology-files-mixed-shelf-215225562.html", "source_name": "MT Newswires", "published_at": "2026-07-09T21:52:25+00:00", "published_display": "09 Jul 2026 21:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Anbio Biotechnology \u2013 NASDAQ:NNNN", "summary": "This article provides financial information for Anbio Biotechnology (NASDAQ:NNNN), specifically focusing on its forward price-to-earnings ratio. The content, sourced from TradingView, indicates \"No trades\" and is primarily a placeholder or incomplete financial data page, emphasiz", "url": "https://www.tradingview.com/symbols/NASDAQ-NNNN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T18:40:11", "published_display": "03 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Anbio Biotechnology Class A \u2013 FWB:N3B", "summary": "This article provides a brief financial overview for Anbio Biotechnology Class A (FWB:N3B), focusing on its price-to-earnings forward metric. The content indicates that market data is provided by ICE Data Services and reference data by FactSet, with all copyrights reserved up to ", "url": "https://www.tradingview.com/symbols/FWB-N3B/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:10:17", "published_display": "30 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Soars After Surprise Media Spotlight", "summary": "Anbio Biotechnology Class A (NNNN) shares are surging after being featured in a Benzinga article on top healthcare stocks for Q2. This rally is attributed to fresh media exposure, renewed optimism for Anbio's diagnostic portfolio, and a technical rebound, rather than broader sect", "url": "https://www.tipranks.com/news/catalyst/anbio-biotechnology-soars-after-surprise-media-spotlight", "source_name": "TipRanks", "published_at": "2026-06-22T14:40:14", "published_display": "22 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top 3 Health Care Stocks You'll Regret Missing In Q2 - iRhythm Holdings (NASDAQ:IRTC), Anbio Biotechnolog", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPb2ZIV3pJcVZ3RUNiXy04TTNESGhKcjdEMG91VGt5eDFkTjdyd2x3OVE1Q1dqSUdxWG1jbDEwbUFUVnpzZTBrZjFfSjZtMDlCWFJNUjJud0Q2LUw2ankyREpuRDZJOThKcFFjTlRFV3BtZWJYMGJoelY0amp3d2R1eVE5V2l2LW1HQlB3MmNYMzBNQmEtQThVWUdaQWZ3aHRHSjFIZmJoTGZ3OW95MUw0eHRnZFNBQm8?oc=5", "source_name": "Benzinga", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Holds Steady Near $34.41 as Trading Volume Remains Moderate - VOLD Alert", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQTWNPLXVBNS1ucGlGVHlLMnlENEFCOWNLR1V0bFBOZmNJd2NGbkhHei1qREpqLTZMbnpKVl9jV1dHbXAyYk10TUZaZUtnbzR6QlByQmVkQ1JLVjY0T1FPOVZ1VGdfSk9tVXRpWlpoUy01NDNibkZKN2doeXVxU3dCWjZZQ2FVZlVXaEYxZXhEdHoxdXpxUm9HTkRnWmFnN2h6bTVyUURBelFwU2FZXzJDa0dnNVRnTVVnSjl5SEJ3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology (NNNN) Surges 5%: Key Levels and What to Watch - Put Dominated", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPM2NGSUpWUkhJWXEzeWxneElLdHdXc0JveURSZk5zNkRTa3o3bXJXSE12VmdZZ1ZYUlp2WWNwMV9ia0x0TUhqaXNxYXFtcW5BVTh1UjVXeDFtWjhyVXQ1WUdNVjYyTEJFMlFJNGNzdjhyRVRCNVY2ZEl3SWliUmZCbWUzVGk2cnBXVnl4TVRrcWxSS2hzYTF4TWloTE9QSEpJMVBvUmdvR2kxOFl1TkhlWkln?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Anbio Biotechnology (NNNN) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Control shifts as Anbio (NNNN) boosts Class B voting power", "summary": "Anbio Biotechnology shareholders have approved significant changes to the company's capital structure and governance, including a Share Capital Reduction, an Authorised Share Capital Increase, and a substantial boost in voting rights for Class B shares from 50 to 500 votes per sh", "url": "https://www.stocktitan.net/sec-filings/NNNN/6-k-anbio-biotechnology-current-report-foreign-issuer-48a739cd67a1.html", "source_name": "Stock Titan", "published_at": "2026-05-19T10:09:26", "published_display": "19 May 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Free cash flow per share of Anbio Biotechnology Class A \u2013 FWB:N3B", "summary": "The article presents information related to the free cash flow per share for Anbio Biotechnology Class A, traded on the Frankfurt Stock Exchange under the symbol N3B. It appears to be a financial data snippet from TradingView, indicating the period, value, and change in free cash", "url": "https://www.tradingview.com/symbols/FWB-N3B/financials-statistics-and-ratios/free-cash-flow-per-share/", "source_name": "TradingView", "published_at": "2026-05-01T13:39:17", "published_display": "01 May 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Calls May 15 Shareholder Votes on Sweeping Capital and Governance Overhaul", "summary": "Anbio Biotechnology (NNNN) is holding shareholder meetings on May 15, 2026, to approve significant changes to its capital and governance structure. These proposed changes include a reduction in par value, a substantial increase in authorized share capital to introduce new Class C", "url": "https://www.tipranks.com/news/company-announcements/anbio-biotechnology-calls-may-15-shareholder-votes-on-sweeping-capital-and-governance-overhaul", "source_name": "TipRanks", "published_at": "2026-04-27T23:09:35", "published_display": "27 Apr 2026 23:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology (NNNN) files 20-F/A to mark well-known seasoned issuer", "summary": "Anbio Biotechnology (NNNN) has filed an Amendment No. 1 to its Form 20-F annual report for the year ended December 31, 2025. The sole purpose of this amendment is to update the cover page to indicate that the company is a well-known seasoned issuer, as defined in Rule 405 of the ", "url": "https://www.stocktitan.net/sec-filings/NNNN/20-f-a-anbio-biotechnology-amends-annual-report-foreign-issuer-56acd8776418.html", "source_name": "Stock Titan", "published_at": "2026-04-09T09:39:42", "published_display": "09 Apr 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Head-To-Head Analysis: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN)", "summary": "This article provides a head-to-head analysis of Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX), comparing them across valuation, earnings, insider and institutional ownership, profitability, and analyst recommendations. Anbio Biotechnology shows higher revenue and ", "url": "https://www.defenseworld.net/2026/03/07/head-to-head-analysis-oncocyte-nasdaqimdx-anbio-biotechnology-nasdaqnnnn-2.html", "source_name": "Defense World", "published_at": "2026-03-09T07:09:43", "published_display": "09 Mar 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Review", "summary": "This article provides a head-to-head comparison between Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX), two manufacturing companies, evaluating them on profitability, earnings, valuation, analyst recommendations, and institutional/insider ownership. Anbio Biotechnol", "url": "https://www.defenseworld.net/2026/03/09/oncocyte-nasdaqimdx-versus-anbio-biotechnology-nasdaqnnnn-head-to-head-review.html", "source_name": "Defense World", "published_at": "2026-03-09T05:51:22", "published_display": "09 Mar 2026 05:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Financial Analysis: Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN)", "summary": "This article compares Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX) based on financial metrics, institutional ownership, analyst recommendations, and profitability. Anbio Biotechnology, a company focused on in vitro diagnostics, demonstrates higher revenue and earn", "url": "https://www.defenseworld.net/2026/03/06/financial-analysis-oncocyte-nasdaqimdx-and-anbio-biotechnology-nasdaqnnnn-2.html", "source_name": "Defense World", "published_at": "2026-03-07T04:53:04", "published_display": "07 Mar 2026 04:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology: Improved Margins, Still Priced For Growth That Isn't Showing Up", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNb2V5ZkdCSDl3MWVheWhudnNHUG1lM20tWUJQQk95SlVGV0FwRmlSX25xYzktZHVfbEU2YWxKMDNDck56RjJXVnRzVFJaWFJOcG5hN2VQZjd5WEFYUU9JUkJiQkN4aHJuX1dhRWdvd2p0aHZQNWhCcnhhUXl0dVVQQWNhYWxLd3ZLNmtuVGJjSTRxd3Z6XzlnSGgycHZVUW1pTFVkb05EbmhHWHFVSk1LZDIwRmJxVmJIODc2Z3NKaDc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head to Head Contrast", "summary": "This article compares Oncocyte (IMDX) and Anbio Biotechnology (NNNN) based on various financial metrics and analyst recommendations. Anbio Biotechnology demonstrates higher revenue and profitability, leading it to outperform Oncocyte in 6 out of 10 comparison factors. The article", "url": "https://www.defenseworld.net/2026/03/01/oncocyte-nasdaqimdx-versus-anbio-biotechnology-nasdaqnnnn-head-to-head-contrast.html", "source_name": "Defense World", "published_at": "2026-03-01T07:52:24", "published_display": "01 Mar 2026 07:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Forecast & Price Prediction 2026\u20132030", "summary": "This article provides a comprehensive stock forecast and price prediction for Anbio Biotechnology Class A Ordinary Shares (NNNN) from 2026 to 2030, and further projections up to 2057. It presents yearly and monthly estimated price ranges, details technical analysis, and includes ", "url": "https://coincodex.com/stock/NNNN/price-prediction/", "source_name": "CoinCodex", "published_at": "2026-03-01T01:51:35", "published_display": "01 Mar 2026 01:51", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Critical Comparison: Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN)", "summary": "This article compares Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX) across various financial metrics, analyst recommendations, and profitability. Anbio Biotechnology outperforms Oncocyte in six out of ten comparison factors, including revenue and earnings. However,", "url": "https://www.defenseworld.net/2026/02/26/critical-comparison-oncocyte-nasdaqimdx-vs-anbio-biotechnology-nasdaqnnnn.html", "source_name": "Defense World", "published_at": "2026-02-27T01:51:35", "published_display": "27 Feb 2026 01:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Comparing Anbio Biotechnology (NASDAQ:NNNN) & Oncocyte (NASDAQ:IMDX)", "summary": "This article compares Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX), two manufacturing companies, across various financial metrics, analyst recommendations, and ownership details. While analysts favor Oncocyte due to a higher potential upside, Anbio Biotechnology s", "url": "https://www.defenseworld.net/2026/02/25/comparing-anbio-biotechnology-nasdaqnnnn-oncocyte-nasdaqimdx-2.html", "source_name": "Defense World", "published_at": "2026-02-25T06:53:24", "published_display": "25 Feb 2026 06:53", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Replaces Auditor to Safeguard 2025 Reporting Timeline", "summary": "Anbio Biotechnology dismissed its auditor, HTL International, LLC, and appointed GGF CPA LTD on February 11, 2026. This change was made to ensure the timely completion of its 2025 Form 20-F financial reporting, with no disagreements cited between Anbio and the former auditor. The", "url": "https://www.tipranks.com/news/company-announcements/anbio-biotechnology-replaces-auditor-to-safeguard-2025-reporting-timeline", "source_name": "TipRanks", "published_at": "2026-02-17T22:57:57", "published_display": "17 Feb 2026 22:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Stock Price Today | NASDAQ: NNNN Live", "summary": "This article provides live stock exchange data for Anbio Biotechnology (NASDAQ: NNNN), including its current stock price, symbol, trading exchange, and various financial metrics. It also features a \"Scorecard\" detailing the company's health, fair value, technical analysis, and re", "url": "https://www.investing.com/equities/anbio-biotechnology", "source_name": "Investing.com", "published_at": "2026-02-04T17:59:09", "published_display": "04 Feb 2026 17:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Class A Shares Surge After Volatility Pause", "summary": "Anbio Biotechnology Class A shares surged following a volatility pause, indicating significant market interest. This rise coincided with the appointment of Michael Zhang as chair of the audit committee, a move designed to enhance governance, investor confidence, and financial tra", "url": "https://www.tipranks.com/news/catalyst/anbio-biotechnology-class-a-shares-surge-after-volatility-pause", "source_name": "TipRanks", "published_at": "2026-02-02T19:28:53", "published_display": "02 Feb 2026 19:28", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology (NNNN) 10K Form and Latest SEC Filings 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE1mNUFlVG1MZnloVDN6WnlZM0ZhQk9Bcy1yLVdFdmMxdk9ZSS1YR1Q1QmR5ZGE0cDVoWGU2UWxWOXl4Qklsd2J4UDY1X2I0M2ZfM3JEeHA2cGZnMDY3QWtiR05sR0pqdzhlWXc?oc=5", "source_name": "MarketBeat", "published_at": "2026-01-28T13:52:53+00:00", "published_display": "28 Jan 2026 13:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026", "summary": "Anbio Biotechnology announced board and committee changes effective January 21, 2026. Michael Zhang has been appointed as a director, the Chair of the Audit Committee, and a member of both the Nominating and Compensation Committees, replacing Kenneth Li. Kenneth Li's departure wa", "url": "https://www.marketscreener.com/news/anbio-biotechnology-announces-board-and-committee-changes-effective-january-21-2026-ce7e5bd8db89f124", "source_name": "www.marketscreener.com", "published_at": "2026-01-26T18:29:41", "published_display": "26 Jan 2026 18:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Strengthens Board Oversight With Appointment of Michael Zhang as Audit Committee Chair", "summary": "Anbio Biotechnology has appointed Michael Zhang as director, audit committee chair, and committee member, effective January 21, 2026. Zhang is recognized as an independent audit committee financial expert under U.S. and Nasdaq rules, and his appointment is expected to enhance the", "url": "https://www.tipranks.com/news/company-announcements/anbio-biotechnology-strengthens-board-oversight-with-appointment-of-michael-zhang-as-audit-committee-chair", "source_name": "TipRanks", "published_at": "2026-01-26T11:58:25", "published_display": "26 Jan 2026 11:58", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology (NASDAQ:NNNN) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxPVHBZYjRPSFlIbGdiczdUZDJ2dUJNejVkV1lhZUJGUnhBVVVVenhBVTZJZFRUNGotYzNYcFpyck56emRmSUYybVNGZHdsbWY4TWhmX1NKMFZhTHYyQ25lT2pQVDBhT1drc1BwQVhJTF9tdWZDVVJ6Q2NkY29QZlRKM3UxSk5KcF9MRnlIYmtTQ1E1SzlSYkdUMmNpbWFydVpLSjN6czNjQTZNT01XUlQ4a1UwS2lxLTl5U2hhNFo4T3czUGkzZEp4bU5RVGdxeUtDT0NMZkF6cU9nTy1jczNMRm1SbE92VnJl0gHuAUFVX3lxTFBNZ0dKbG9DM09qX2pabUVCMDVoRF9QWTdBWE51dHNDWWxwbFhQQlVaZmhzTTg5OWt4c3M2dnlfem82ak5ibENUdElBY29DOEx6MmZla0E1X0ZLOE00R25KcS1ZRHJXN0VZRnFzZUtxc0Z0NnkzQ0lYMkZtYV9uT1M2TzdOakRueEVvT0M4eUNCR2lsZU5aVTRGenJfS05zbVVta1BKVlJVOEY5cjZPSWRVc05xeVJ1Z0lvQV92WWM4c2VTYVU4M0dIei14RGJGWUlmZkFBM0xxSVc0UUtDeVdGRUpRaXV5dEo0SXdpc0E?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-01T08:00:00+00:00", "published_display": "01 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Posts Higher Margins and Profits Despite Revenue Dip in First Half of 2025", "summary": "Anbio Biotechnology (NNNN) reported financial results for the first half of 2025, showing a revenue decrease to $4.6 million from $5.8 million, but a significant rise in gross profit to $4.2 million, with margins expanding to 92.3%. Net income also increased to $3.8 million, demo", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NNNN-Q/pressreleases/36846367/anbio-biotechnology-posts-higher-margins-and-profits-despite-revenue-dip-in-first-half-of-2025/", "source_name": "The Globe and Mail", "published_at": "2026-01-01T03:09:49", "published_display": "01 Jan 2026 03:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Year-End Review | The 2025 US IPO Gainers List is Out! Anbio Biotechnology Soars Over 570%, 'First Stablecoin Stock' Circle Surges More Than 180%", "summary": "The 2025 U.S. IPO market saw a significant recovery, driven by a stabilizing macroeconomic environment and renewed investor confidence, with 202 IPOs raising $44 billion. Technology and healthcare companies dominated the top performers, highlighting 'polarization' and 'sector foc", "url": "https://news.futunn.com/en/post/66532350/year-end-review-the-2025-us-ipo-gainers-list-is", "source_name": "\u5bcc\u9014\u8d44\u8baf", "published_at": "2025-12-27T06:58:33", "published_display": "27 Dec 2025 06:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NNNN SEC Filings - ANBIO BIOTECHNOLOGY 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for ANBIO BIOTECHNOLOGY (NNNN) SEC filings, including 10-K, 10-Q, 8-K reports, and insider trading forms. It details recent filings such as initial Form 3 reports from directors and executives, and significant corporate actions like cha", "url": "https://www.stocktitan.net/sec-filings/NNNN/", "source_name": "Stock Titan", "published_at": "2025-11-14T00:39:22", "published_display": "14 Nov 2025 00:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Anbio Biotechnology\u2019s Stock is Tumbling - TipRanks", "summary": "Anbio Biotechnology Class A (NNNN) is experiencing significant stock volatility, including recent trading halts due to large price swings. The stock initially surged but has faced multiple declines, reflecting investor uncertainty and broader market conditions affecting its perce", "url": "https://www.tipranks.com/news/catalyst/why-anbio-biotechnologys-stock-is-tumbling", "source_name": "TipRanks", "published_at": "2025-10-13T16:24:27", "published_display": "13 Oct 2025 16:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NNNN News Today | Why did Anbio Biotechnology stock go up today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYEFVX3lxTE5EM0g0bU9zZHpHVlVsWG5ZZGR4NGdrMXNuVEVRUkdWT0V3bUR6VERHVXVxckpWNEg4c3ItakRNcWdBRFBGbW9lVmZpMDREbkhESXh3NlFhMl9QUVZBTjBGSA?oc=5", "source_name": "MarketBeat", "published_at": "2025-09-18T17:08:47+00:00", "published_display": "18 Sep 2025 17:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here Is What You Need To Know Before Investing In Anbio Biotechnology (NNNN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOUjZDV2wtYTdmNVh3ZGNlRmhNNUVIdlFCb3VsMXNXaWJBbDJ5MUswOHJydlI1UUY0TjRBOGp6NnBfQ2NWZzN5dDYwbERfd3VwSldUYm5NQmlBTGVPQkN2Vk9hNWxuRm1qdW0tdTNBQTNlTlZvM09xd2lMV0FqREFEVDlkSElzZ3Q1dGJZdGpR?oc=5", "source_name": "Market source", "published_at": "2025-07-11T07:00:00+00:00", "published_display": "11 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANBIO BIOTECHNOLOGY (NNNN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9YMmdjUmlWVjc0Uzl6bG16RWlEYlB2MzBHNWRSRU5fZkpWWV9wdXZfaXdLa2NmSWM1dHU1aE1XRm9ROXc3LTItbGlWVUt0SlFiOFhn?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-28T14:05:31+00:00", "published_display": "28 Apr 2025 14:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NNNN Stock Price, News & Analysis", "summary": "Anbio Biotechnology (Nasdaq: NNNN) is a global in vitro diagnostics (IVD) company specializing in diagnostic products for human and veterinary health, utilizing five key platforms for biomarker detection. The company has a global presence across the EU, APAC, and the Americas, wi", "url": "https://www.stocktitan.net/overview/NNNN/", "source_name": "Stock Titan", "published_at": "2025-04-28T09:39:09", "published_display": "28 Apr 2025 09:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Free float of Anbio Biotechnology \u2013 NASDAQ:NNNN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOekFTYnBNdVhKT01rODZmR2ZRT3ZIVGwwbXEzaThFdzdfcFpiSUI2engxRTdOTTN0NFlsR1pYSy1HOGdwOEoyLTFlWXBpWlJaM1NVTU9HZmR3NHZjRmdhNXdXaWt3NXNidlUzNHpoUnVBeUpOdFFaMjEzY2tTVlZraGVTUE55dTQtNTJXc0xaMmRFdl82NUNtUmZKN1FuSFNZV1lRbHdQVk9odw?oc=5", "source_name": "TradingView", "published_at": "2025-03-16T05:17:58+00:00", "published_display": "16 Mar 2025 05:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology (NNNN) Company Information", "summary": "This report provides comprehensive company information for Anbio Biotechnology (NNNN), detailing its market capitalization, employee growth, and exchange listings. It includes key data like the company's founding year, industry, sector, shares outstanding, and website. The report", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nnnn/anbio-biotechnology/information", "source_name": "Simply Wall Street", "published_at": "2025-02-21T10:08:51", "published_display": "21 Feb 2025 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology (NNNN) Leadership & Management Team Analysis", "summary": "This article provides an analysis of Anbio Biotechnology's leadership and management team. It details information about CEO Michael Lau's compensation and tenure, along with an overview of the leadership team and board members. The report also includes recent management updates a", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nnnn/anbio-biotechnology/management", "source_name": "Simply Wall St", "published_at": "2025-02-21T04:52:03", "published_display": "21 Feb 2025 04:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Anbio Biotechnology (NNNN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9Wc1Zuci1YdW56SjFJMUFyaWpOQmZ1N0Y1ZlpRTlpYdU5sUjlIaEpSS18teFlXOW9rUDAyR1lpVUF5LUFSYXlmNTdkaVA3LURxUzhTUGJqbkZUSFNIc3dpWFBKMmF4TWNjN3lScQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-02-21T02:43:38+00:00", "published_display": "21 Feb 2025 02:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Announces Closing of Initial Public Offering", "summary": "Anbio Biotechnology has announced the closing of its initial public offering, raising gross proceeds of US$8 million from the sale of 1,600,000 Class A ordinary shares at US$5.00 each. The shares began trading on the Nasdaq Global Market under the ticker symbol \"NNNN\" on February", "url": "https://www.globenewswire.com/news-release/2025/02/20/3029797/0/en/anbio-biotechnology-announces-closing-of-initial-public-offering.html", "source_name": "GlobeNewswire", "published_at": "2025-02-20T12:40:43", "published_display": "20 Feb 2025 12:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NNNN - ANBIO BIOTECHNOLOGY Latest Stock News & Market Updates", "summary": "This page provides the latest news and market updates for Anbio Biotechnology (NNNN), a global in vitro diagnostics company. It highlights recent product launches, such as the Chikungunya Rapid Test and the AP-100 Ultra-Fast PCR system, as well as the company's participation in i", "url": "https://www.stocktitan.net/news/NNNN/", "source_name": "Stock Titan", "published_at": "2025-02-20T09:57:45", "published_display": "20 Feb 2025 09:57", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anbio Biotechnology Closes Initial Public Offering, Raising $8 Million on Nasdaq", "summary": "Anbio Biotechnology has successfully completed its initial public offering, raising $8 million by offering 1,600,000 Class A ordinary shares at $5.00 each. The shares commenced trading on Nasdaq under the ticker \"NNNN\" on February 19, 2025. The capital will be utilized for expand", "url": "https://www.nasdaq.com/articles/anbio-biotechnology-closes-initial-public-offering-raising-8-million-nasdaq", "source_name": "Nasdaq", "published_at": "2025-02-20T08:09:19", "published_display": "20 Feb 2025 08:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANBIO BIOTECHNOLOGY (NNNN) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE9QMDg1US1yaTlPcVJCYXZEanNRMUpWemRyRWplNGRlcFJDWUR5SVY5YmhISVlTQWp1WjZQcXFMZk9yeU9RUFVFNXlwbVVvQQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-02-20T08:00:00+00:00", "published_display": "20 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NNNN Stock Price and Chart \u2014 NASDAQ:NNNN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1wU25tMms5WVliZG5Bc1Z3SUtzb19ydkVnTG43ZzdEdGpfRWkwcWpQZDJMV29NeUJ5cFA1di1nUWo3TjJXM2hXUHh0TkZjTEpkRlVZZEJYNFZuQjVs?oc=5", "source_name": "TradingView", "published_at": "2025-02-19T18:21:46+00:00", "published_display": "19 Feb 2025 18:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 87, "total_relevant": 44, "sentiment_summary": {"positive": 15, "negative": 2, "neutral": 27, "score": 56, "total": 44, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 18.3, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 9.39, "latest_week": "2026-07-10", "one_week_move": -26.1, "four_week_move": -39.8, "twelve_week_move": -65.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.834273, "market_dynamics_buy_signal": false, "relative_strength": -73.422019, "fair_value_gap": -62.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "positive", "expectation_probability": 59.3007, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-26.1% over one week, -39.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 7}, {"label": "TipRanks", "count": 6}, {"label": "Defense World", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "simplywall.st", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "MT Newswires", "count": 1}, {"label": "Benzinga", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 7}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-26.1% over one week, -39.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Anbio Biotechnology Files Mixed Shelf Registration"}], "updated_at": "2026-07-17T02:55:51.954439+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}